1. Araki, S., et al., Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS One, 2015. 10(1): p. e0116929.DOI: 10.1371/journal.pone.0116929. https://www.ncbi.nlm.nih.gov/pubmed/25581376
2. Bullock, A.N., et al., Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure, 2009. 17(3): p. 352-62.DOI: 10.1016/j.str.2008.12.023. https://www.ncbi.nlm.nih.gov/pubmed/19278650
3. Corkery, D.P., et al., Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response. Nucleus, 2015. 6(4): p. 279-88.DOI: 10.1080/19491034.2015.1062194. https://www.ncbi.nlm.nih.gov/pubmed/26098145
4. Funnell, T., et al., CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor. Nat Commun, 2017. 8(1): p. 7.DOI: 10.1038/s41467-016-0008-7. https://www.ncbi.nlm.nih.gov/pubmed/28232751
5. Iwai, K., et al., Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability. EMBO Mol Med, 2018. 10(6).DOI: 10.15252/emmm.201708289. https://www.ncbi.nlm.nih.gov/pubmed/29769258
6. jain, P., et al., Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Curr Drug Targets, 2014. 15(5): p. 539-50.DOI: 10.2174/1389450115666140226112321. https://www.ncbi.nlm.nih.gov/pubmed/24568585
7. Koedoot, E., et al., Splicing regulatory factors in breast cancer hallmarks and disease progression. Oncotarget, 2019. 10(57): p. 6021-6037.DOI: 10.18632/oncotarget.27215. https://www.ncbi.nlm.nih.gov/pubmed/31666932
8. Sako, Y., et al., Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy. Sci Rep, 2017. 7: p. 46126.DOI: 10.1038/srep46126. https://www.ncbi.nlm.nih.gov/pubmed/28555643